19P Effects of CTLA-4 single nucleotide polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma

K.D Joode,H Läubli,R.A.F Von Moos,A Zippelius,A.A.M Van Der Veldt,S Meyer,S Aeppli,O.A Michielin,C.L Gerard,C Mangas,A Rojas Mora,M.P Levesque,R.H Mathijssen,S Leoni-Parvex,Y Metaxas,J Mangana,M Joerger,R Van Schaik

doi:10.1016/j.iotech.2022.100124

19P Effects of CTLA-4 single nucleotide polymorphisms (SNPs) on toxicity of ipilimumab-containing regimens in patients with advanced stage melanoma

K.D Joode, H Läubli + Show 16 more

Open Access

https://doi.org/10.1016/j.iotech.2022.100124

Copy DOI

Journal: Immuno-Oncology and Technology	Publication Date: Dec 1, 2022
License type: cc-by-nc-nd

Affiliation: University Hospital of Basel, University of Basel, Kantonsspital Graubünden, Swiss Red Cross, University of St. Gallen, Ospedale Regionale di Bellinzona e Valli, Swiss Group For Clinical Cancer Research, University Hospital of Zurich, Erasmus MC Cancer Institute, Erasmus MC, Istituto Cantonale di Patologia, Kantonsspital Münsterlingen

#Single Nucleotide Polymorphisms #Cytotoxic T-lymphocyte-associated Protein 4 + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

SNPs of the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, an inhibitor of T cell priming, are associated with auto- and allo-immunity. Previously, studies implied a role for these SNPs as surrogate markers for outcome in melanoma patients treated with immune checkpoint inhibitors. However, no predictive SNPs are defined to date. The primary aim of this study was to analyze different CTLA-4 SNPs in a large real-world cohort of melanoma patients treated with ipilimumab and to correlate these SNPs with toxicity and survival.

Full Text